See more : Almawarid Manpower Company (1833.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Yield10 Bioscience, Inc. (YTEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yield10 Bioscience, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Forma Therapeutics Holdings, Inc. (FMTX) Income Statement Analysis – Financial Results
- TV Azteca, S.A.B. de C.V. (AZTEF) Income Statement Analysis – Financial Results
- Boiron SA (0DTF.L) Income Statement Analysis – Financial Results
- Doric Nimrod Air One Limited (DNA.L) Income Statement Analysis – Financial Results
- Banc of California, Inc. (BANC) Income Statement Analysis – Financial Results
Yield10 Bioscience, Inc. (YTEN)
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00K | 450.00K | 614.00K | 799.00K | 806.00K | 556.00K | 944.00K | 1.16M | 2.59M | 2.80M | 5.39M | 42.32M | 1.43M | 448.00K | 1.43M | 1.56M | 1.68M | 4.59M | 2.78M | 3.68M | 2.38M | 1.99M |
| Cost of Revenue | 290.00K | 656.00K | 578.00K | 5.22M | 4.85M | 4.78M | 4.60M | 5.67M | 660.00K | 1.48M | 3.03M | 1.43M | 24.45M | 23.67M | 24.47M | 24.67M | 19.90M | 11.24M | 5.98M | 5.43M | 0.00 | 0.00 |
| Gross Profit | -230.00K | -206.00K | 36.00K | -4.42M | -4.04M | -4.23M | -3.65M | -4.51M | 1.93M | 1.32M | 2.37M | 40.89M | -23.02M | -23.23M | -23.05M | -23.11M | -18.22M | -6.65M | -3.20M | -1.75M | 2.38M | 1.99M |
| Gross Profit Ratio | -383.33% | -45.78% | 5.86% | -553.32% | -501.49% | -760.25% | -386.97% | -389.21% | 74.56% | 47.07% | 43.90% | 96.63% | -1,615.44% | -5,184.15% | -1,617.26% | -1,486.30% | -1,082.47% | -144.77% | -115.04% | -47.53% | 100.00% | 100.00% |
| Research & Development | 8.32M | 7.75M | 6.20M | 5.36M | 4.85M | 4.78M | 4.60M | 5.67M | 16.57M | 17.34M | 19.13M | 23.18M | 0.00 | 0.00 | 0.00 | 24.67M | 19.90M | 11.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 3.83M | 3.25M | 0.00 | 2.64M |
| Other Expenses | 0.00 | 41.00K | -3.00K | 83.00K | 21.00K | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 25.68M | 28.15M | 32.87M | 37.29M | 15.84M | 15.71M | 15.68M | 40.45M | 35.50M | 22.11M | 3.83M | 3.25M | 0.00 | 7.05M |
| Cost & Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 26.34M | 29.63M | 35.90M | 38.71M | 40.29M | 39.39M | 40.15M | 40.45M | 35.50M | 22.11M | 9.81M | 8.68M | 0.00 | 7.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 158.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 5.94M | 1.47M | 109.36K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 13.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00K | 0.00 | 772.00K | 2.89M | 0.00 | 5.00K | 10.14K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 290.00K | 656.00K | 578.00K | 611.00K | 1.83M | 784.00K | 206.00K | 177.00K | 265.00K | 507.00K | 928.00K | 1.30M | 1.51M | 1.65M | 2.73M | 3.73M | 1.45M | 964.00K | 314.57K | 265.25K | 0.00 | 0.00 |
| EBITDA | -14.13M | -13.19M | -11.47M | -9.43M | -8.39M | -9.12M | -9.08M | -10.07M | -12.35M | -26.32M | -27.61M | 4.90M | -37.35M | -37.29M | -36.00M | -35.16M | -32.37M | -16.56M | -6.71M | -4.73M | 2.38M | -5.06M |
| EBITDA Ratio | -23,545.00% | -2,930.67% | -1,982.41% | -1,101.75% | -609.93% | -1,640.83% | -949.58% | -836.50% | -907.48% | -942.25% | -547.26% | 11.58% | -2,621.33% | -8,324.11% | -2,525.96% | -2,261.16% | -1,923.05% | -360.78% | -216.11% | -128.73% | 100.00% | -254.60% |
| Operating Income | -14.42M | -13.45M | -11.69M | -9.61M | -8.60M | -9.32M | -9.28M | -10.25M | -23.74M | -26.83M | -30.50M | 3.60M | -38.86M | -38.94M | -38.73M | -38.89M | -33.82M | -17.52M | -7.02M | -5.00M | 2.38M | -5.06M |
| Operating Income Ratio | -24,028.33% | -2,989.11% | -1,904.23% | -1,202.63% | -1,066.50% | -1,676.08% | -983.37% | -884.21% | -915.30% | -958.18% | -565.48% | 8.51% | -2,727.09% | -8,691.74% | -2,717.82% | -2,501.09% | -2,009.27% | -381.79% | -252.59% | -135.94% | 100.00% | -254.60% |
| Total Other Income/Expenses | -38.00K | 41.00K | 697.00K | -541.00K | -4.61M | 134.00K | -113.00K | -38.00K | 29.00K | 61.00K | -4.00K | 27.00K | 76.00K | 136.00K | 0.00 | 0.00 | 5.94M | 1.46M | -699.64K | 0.00 | -2.38M | 5.06M |
| Income Before Tax | -14.46M | -13.41M | -11.00M | -10.15M | -13.21M | -9.19M | -9.40M | -10.29M | -23.68M | -26.77M | -30.51M | 3.63M | -38.79M | -38.80M | 0.00 | 0.00 | -27.88M | -16.06M | -7.72M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -24,091.67% | -2,980.00% | -1,790.72% | -1,270.34% | -1,638.96% | -1,651.98% | -995.34% | -887.49% | -912.91% | -956.00% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | 0.00% | 0.00% | -1,656.27% | -349.93% | -277.76% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 156.00K | 36.00K | 56.00K | -254.00K | 104.00K | 113.00K | -1.10M | -62.00K | 2.71M | 4.00K | 0.00 | 0.00 | 0.00 | -772.00K | -2.89M | 0.00 | 0.00 | 600.79K | 54.31K | 6.64M | 5.19M |
| Net Income | -14.46M | -13.57M | -11.03M | -10.21M | -12.96M | -9.19M | -9.40M | -7.60M | -23.68M | -29.53M | -30.51M | 3.63M | -38.79M | -38.80M | -37.96M | -36.01M | -27.88M | -16.06M | -7.63M | -5.05M | -6.64M | -5.19M |
| Net Income Ratio | -24,091.67% | -3,014.67% | -1,796.58% | -1,277.35% | -1,607.44% | -1,651.98% | -995.34% | -656.08% | -912.91% | -1,054.79% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | -2,663.65% | -2,315.43% | -1,656.27% | -349.93% | -274.20% | -137.42% | -278.62% | -260.83% |
| EPS | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -149.23K | -79.89K | -158.62K | -100.88K |
| EPS Diluted | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -121.96K | -79.89K | -158.62K | -100.88K |
| Weighted Avg Shares Out | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 588.00 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 51.10 | 63.27 | 41.86 | 51.43 |
| Weighted Avg Shares Out (Dil) | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 589.07 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 62.52 | 63.27 | 41.86 | 51.43 |
Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production
Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform
'Stay Hungry, Stay Foolish' Small Cap Strategies With Courage & Conviction Investing
Courage & Conviction Investing discusses why small cap investors should stay committed and have conviction in their ideas despite market drawdowns. Why he's never been more bullish on Advanced Emissions Solutions.
Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference
WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held on September...
Yield10 Bioscience Announces Closing of $3.7 Million Public Offering
WOBURN, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the closing of its previously announced public offering of 5,750,000 units at a public offering price of $0.65...
Yield10 Bioscience, Inc. (YTEN) Q2 2023 Earnings Call Transcript
Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Lynne Brum – Vice President of Planning and Corporate Communications Oli Peoples – Chief Executive Officer Kristi Snell – Vice President of...
Yield10 Bioscience Announces Second Quarter 2023 Financial Results
-Harvesting underway for contracted winter and spring Camelina acres for the biofuels market -Reported positive results in first field tests of stacked herbicide tolerant Camelina -Filed a request for regulatory status review with USDA-APHIS for omega-3 (EPA) Camelina -Strengthened balance...
Yield10 Bioscience to Announce Second Quarter 2023 Financial Results and Host a Conference Call on Monday, August 14, 2023
WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its second quarter 2023 financial results and provide a corporate update on Monday,...
Yield10 Bioscience Announces Pricing of $3.7 Million Public Offering
WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the pricing of its public offering of 5,750,000 units at a public offering price of $0.65 per unit....
Why is Yield10 Bioscience (YTEN) Stock Down 46% Today?
Yield10 Bioscience (NASDAQ: YTEN ) stock is falling hard on Friday after a public share offering went into effect. The company has filed its notice of effectiveness for this share offering but hasn't provided an updated press release with the details...
Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market
-Findings demonstrate a key advancement in the development of proprietary Camelina varieties tolerant to application of broadleaf weed control as well as to Group 2 soil residual herbicide chemistries
Source: https://incomestatements.info
Category: Stock Reports